Kurs & Likviditet
-0,05%
|
6,62 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2023-11-08 | Kvartalsrapport 2023-Q3 |
2023-08-09 | Kvartalsrapport 2023-Q2 |
2023-05-10 | Kvartalsrapport 2023-Q1 |
2023-05-04 | Ordinarie utdelning PHO 0.00 NOK |
2023-05-03 | Årsstämma 2023 |
2023-02-24 | Bokslutskommuniké 2022 |
2023-02-23 | Bokslutskommuniké 2022 |
2022-11-02 | Kvartalsrapport 2022-Q3 |
2022-08-10 | Kvartalsrapport 2022-Q2 |
2022-05-11 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2022-04-28 | Årsstämma 2022 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-11-17 | Kvartalsrapport 2021-Q3 |
2021-08-11 | Kvartalsrapport 2021-Q2 |
2021-07-28 | Extra Bolagsstämma 2021 |
2021-05-21 | Ordinarie utdelning PHO 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-05-19 | Kvartalsrapport 2021-Q1 |
2021-03-03 | Bokslutskommuniké 2020 |
2020-11-10 | Kvartalsrapport 2020-Q3 |
2020-08-18 | Kvartalsrapport 2020-Q2 |
2020-06-11 | Ordinarie utdelning PHO 0.00 NOK |
2020-06-10 | Årsstämma 2020 |
2020-05-07 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-07 | Kvartalsrapport 2019-Q3 |
2019-08-07 | Kvartalsrapport 2019-Q2 |
2019-06-19 | Extra Bolagsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-05-10 | Ordinarie utdelning PHO 0.00 NOK |
2019-05-09 | Årsstämma 2019 |
2019-02-27 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-08 | Kvartalsrapport 2018-Q2 |
2018-05-23 | Kvartalsrapport 2018-Q1 |
2018-05-11 | Ordinarie utdelning PHO 0.00 NOK |
2018-05-09 | Årsstämma 2018 |
2018-02-27 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-23 | Kvartalsrapport 2017-Q2 |
2017-05-23 | Kvartalsrapport 2017-Q1 |
2017-04-28 | Ordinarie utdelning PHO 0.00 NOK |
2017-04-27 | Årsstämma 2017 |
2017-02-15 | Bokslutskommuniké 2016 |
2016-11-15 | Kvartalsrapport 2016-Q3 |
2016-08-23 | Kvartalsrapport 2016-Q2 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2016-04-28 | Årsstämma 2016 |
2016-02-11 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-06 | Kvartalsrapport 2015-Q1 |
2015-05-02 | Ordinarie utdelning PHO 0.00 NOK |
2015-04-30 | Årsstämma 2015 |
2015-02-12 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-26 | Kvartalsrapport 2014-Q2 |
2014-05-28 | Ordinarie utdelning PHO 0.00 NOK |
2014-05-27 | Årsstämma 2014 |
2014-05-07 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-10-23 | Kvartalsrapport 2013-Q3 |
2013-08-22 | Kvartalsrapport 2013-Q2 |
2013-05-23 | Ordinarie utdelning |
2013-05-22 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-10-26 | Kvartalsrapport 2012-Q3 |
2012-08-24 | Kvartalsrapport 2012-Q2 |
2012-05-10 | Årsstämma 2012 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-02-16 | Bokslutskommuniké 2011 |
2011-10-26 | Kvartalsrapport 2011-Q3 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-04-27 | Kvartalsrapport 2011-Q1 |
2011-04-27 | Årsstämma 2011 |
2011-02-17 | Bokslutskommuniké 2010 |
2010-10-27 | Kvartalsrapport 2010-Q3 |
2010-08-19 | Kvartalsrapport 2010-Q2 |
2010-04-28 | Kvartalsrapport 2010-Q1 |
2010-02-19 | Bokslutskommuniké 2009 |
2009-11-26 | Bonusutdelning |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2022-08-09 09:38:13
On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company
specializing in the discovery and development of innovative drugs for the
treatment of genitourinary tumors and other major diseases, announced that the
multinational Phase III Clinical Trial of APL-1702 (Cevira[®]), a novel non
-surgical treatment of cervical high-grade squamous intraepithelial lesions
(HSIL), has successfully enrolled 402 patients in the study two months ahead of
schedule. Additionally, Photocure received a $1 million milestone payment from
Asieris related to the ongoing clinical development of Cevira.
APRICITY is a multicenter, prospective, double-blind, randomized controlled
Phase III study further evaluating the efficacy and safety of the integrated
drug-and light-delivery device Cevira[®] in the treatment of HSIL. The clinical
trial was approved by the National Medical Products Administration (NMPA) in
July 2020 and was conducted simultaneously at 65 sites in 8 countries including
China, Germany, Hungary and the Netherlands. The first patient was dosed in
November 2020.
Cervical cancer is the fourth most common cancer in women worldwide[1]. In 2020,
604,000 new cases and 342,000 deaths worldwide were attributed to cervical
cancer.[1,2 ]Current treatments of HSIL of the cervix are based on invasive
surgical interventions, compromising cervical competence and functionality.
Currently, no non-surgical approach is available for the treatment of
precancerous cervical lesions.
Read Asieris' full press release here: https://asieris.com/asieris-multinational
-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed
-enrollment/
1. Cervical cancer. Available from: https://www.who.int/health-topics/cervical
-cancer
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021